Aspire BioPharma, Inc. (ASBP) Income Statement
ASBP 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsASBP revenue and net income
Where ASBP's revenue goes
2025Each bar shows an amount and its share of revenue. ASBP kept −394,725.1% of revenue as net income.
ASBP profit margins
ASBP growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ASBP quarterly EPS vs estimates
Next report: November 13, 2026.
ASBP income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6,202 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6,318 | $0 | $0 | $0 | — |
| Gross profit | −$116 | $0 | $0 | $0 | — |
| Research & development | $923,914 | $144,356 | $72,050 | $175,316 | — |
| Sales, general & admin | $18.4M | $1.1M | $1.3M | $976,345 | $27,791 |
| Total operating expenses | $19.4M | $1.2M | $1.3M | $976,345 | $25,475 |
| Operating income | −$19.4M | −$1.2M | −$1.3M | −$976,345 | −$25,480 |
| Interest income | — | $548,676 | $5.8M | — | — |
| Interest expense | $8.5M | $97,988 | $8,966 | $0 | — |
| Income before taxes | −$24.5M | −$1.3M | $4.5M | $3.3M | −$25,475 |
| Income taxes | — | $1,013 | $481 | $626 | — |
| Net income | −$24.5M | −$1.3M | $4.5M | $3.3M | −$25,475 |
| EBITDA | −$11.3M | −$1.2M | $5.8M | −$976,345 | −$25,480 |
| EPS (diluted) | −$85.27 | −$498.78 | $39.17 | $0.09 | −$0.04 |
| Gross margin | −1.9% | — | — | — | — |
| Operating margin | −312,016.9% | — | — | — | — |
| Net margin | −394,725.1% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63,103 | $28,353 | $4,261 | $1,941 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $50,818 | $22,603 | $5,261 | $1,057 | $0 | $0 | — | $0 | $0 | — | $0 | $0 |
| Gross profit | $12,286 | $5,750 | −$1,000 | $884 | $0 | $0 | — | $0 | $0 | — | $0 | $0 |
| Research & development | $233,482 | $296,723 | $100,035 | $207,899 | $352,887 | $263,093 | $116,356 | $7,000 | $10,500 | $10,500 | $10,500 | $14,775 |
| Sales, general & admin | $2.2M | $1.4M | $1.7M | $938,482 | $447,003 | $15.3M | $2.7M | $208,256 | $501,012 | $2.5M | $402,615 | $255,257 |
| Total operating expenses | $2.5M | $1.7M | $1.8M | $1.1M | $799,890 | $15.6M | $2.5M | $215,256 | $96,923 | $2.5M | $402,615 | $324,742 |
| Operating income | −$2.4M | −$1.6M | −$1.8M | −$1.1M | −$799,890 | −$15.6M | −$2.5M | −$215,256 | −$501,000 | −$2.5M | −$402,615 | −$324,742 |
| Interest income | $56,676 | $5,009 | — | — | $0 | $0 | — | — | — | — | — | — |
| Interest expense | $0 | $1.6M | $6.2M | $1.5M | $527,893 | $289,931 | $891,624 | $8,496 | $208,184 | $183,310 | $8,966 | $0 |
| Income before taxes | −$1.3M | −$3.2M | −$4.7M | −$1.9M | −$2.0M | −$15.9M | −$12.0M | −$215,256 | −$602,000 | −$2.5M | −$150,913 | −$69,258 |
| Income taxes | — | — | — | — | — | −$1,013 | −$1,013 | $1,013 | — | — | $481 | — |
| Net income | −$1.3M | −$3.2M | −$4.7M | −$1.9M | −$2.0M | −$15.9M | −$12.0M | −$216,269 | −$602,000 | −$2.5M | −$150,913 | −$69,258 |
| EBITDA | −$2.4M | −$62,279 | $4.1M | $1.7M | −$1.5M | −$15.7M | −$11.1M | −$215,256 | $2.0M | −$2.3M | −$402,615 | −$324,742 |
| EPS (diluted) | $1.00 | −$20.57 | −$39.97 | −$44.84 | −$0.04 | −$0.42 | −$1.15 | −$82.99 | −$85.37 | −$329.27 | −$20.14 | −$9.24 |
| Gross margin | 19.5% | 20.3% | −23.5% | 45.5% | — | — | — | — | — | — | — | — |
| Operating margin | −3,880.6% | −5,806.0% | −43,403.5% | −59,015.8% | — | — | — | — | — | — | — | — |
| Net margin | −2,009.6% | −11,367.0% | −110,484.3% | −95,337.1% | — | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ASBP's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ASBP financial results
In fiscal year 2025 (ended December 31, 2025), Aspire BioPharma reported revenue of $0.0 million. It had a net loss of $24.5 million, a net profit margin of −394,725.1%. Diluted earnings per share came to −$85.27.
See the ASBP stock overview for the latest quote and news, or the ASBP chart for price history and technical indicators.
ASBP income statement FAQ
What is Aspire BioPharma's annual revenue?
Aspire BioPharma reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025.
Is Aspire BioPharma profitable?
No. Aspire BioPharma reported a net loss of $24.5 million in fiscal 2025, a net profit margin of −394,725.1%; its operating margin was −312,016.9%.
What is Aspire BioPharma's gross margin?
Aspire BioPharma's gross margin was −1.9% in fiscal 2025: for every $100 of revenue, Aspire BioPharma kept $-2 after the direct cost of its products and services.
How much does Aspire BioPharma spend on research and development?
Aspire BioPharma spent $0.9 million on research and development in fiscal 2025, 14,897.0% of revenue.
What are Aspire BioPharma's earnings per share?
Aspire BioPharma earned $-85.27 per diluted share in fiscal 2025, compared with $-498.78 a year earlier.
When will Aspire BioPharma report its next earnings?
Aspire BioPharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Aspire BioPharma's fiscal year end?
Aspire BioPharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.